| Overview |
| bs-3251R-Cy5.5 |
| 5-Lipoxygenase(Ser271) Antibody, Cy5.5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from rat 5-Lipoxygenase around the phosphorylation site of Ser271 |
| Ser271 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 240 |
| Cytoplasm, Nucleus, Cell membrane |
| 5-lipoxygenase; 5 LO; 5LPG; ALOX 5; ALOX5; Arachidonate 5 lipoxygenase; Arachidonic acid 5 lipoxygenase; Leukotriene A4 synthase; LOG 5; LOG5; MGC163204; LOX5_HUMAN. |
| This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants have been observed, but their full-length nature has not been determined. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz